Inventiva Logo

Inventiva

Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.

IVA | PA

Overview

Corporate Details

ISIN(s):
FR0013233012 (+2 more)
LEI:
969500I9Y690B3FZW590
Country:
France
Address:
50 RUE DE DIJON, 21121 DAIX
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Inventiva is a clinical-stage biopharmaceutical company focused on the development of novel oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets mucopolysaccharidoses (MPS). Inventiva's pipeline is supported by a proprietary discovery engine with an extensive library of 240,000 compounds, a wholly-owned R&D facility, and expertise in targeting nuclear receptors and transcription factors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:56
Regulatory News Service
Franchissement de seuils
French 120.1 KB
2025-11-28 15:42
Major Shareholding Notification
Franchissement de seuils
French 121.1 KB
2025-11-28 15:25
Major Shareholding Notification
Franchissement de seuils
French 110.0 KB
2025-11-13 15:21
ISS
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au…
French 353.4 KB
2025-11-13 15:21
ISS
Inventiva announces pricing of upsized public offering of approximately $150M o…
English 349.5 KB
2025-09-29 00:00
Interim Report
RFS
French 927.7 KB
2025-08-25 09:57
Major Shareholding Notification
Franchissement de seuil
French 114.0 KB
2025-08-25 09:56
Major Shareholding Notification
Franchissement de seuil
French 112.0 KB
2025-08-19 15:35
Major Shareholding Notification
Franchissement de seuil
French 116.8 KB
2025-08-19 15:32
Major Shareholding Notification
Franchissement de seuil
French 116.7 KB
2025-08-19 15:19
Major Shareholding Notification
Franchissement de seuil
French 116.1 KB
2025-08-12 15:57
Major Shareholding Notification
Franchissement de seuil
French 113.9 KB
2025-08-12 15:52
Major Shareholding Notification
Franchissements de seuil
French 121.6 KB
2025-08-11 15:14
Major Shareholding Notification
Franchissement de seuil
French 121.9 KB
2025-06-17 17:02
Major Shareholding Notification
Franchissement de seuils
French 113.4 KB

Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventiva

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventiva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-05 N/A Other Buy 10,000 N/A
2023-12-08 N/A Other Buy 15,000 N/A

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.